Idorsia (XSWX:IDIA) Other Long-Term Liabilities: CHF194.7 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:IDIA Idorsia Ltd XSWX:IDIA
48 GF Score
Price CHF6.63
GF Value CHF2.90
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Idorsia Other Long-Term Liabilities?

Idorsia XSWX:IDIA +7.54% 48 Other Long-Term Liabilities is CHF194.7 Mil as of Mar. 2026. GuruFocus rates XSWX:IDIA with a GF Score™ of 48/100 and a GF Value™ of CHF2.90 (Significantly Overvalued). The stock has 1 warning sign investors should review.

Idorsia's other long-term liabilities for the quarter that ended in Mar. 2026 was CHF194.7 Mil.

Idorsia's quarterly other long-term liabilities declined from Sep. 2025 (CHF198.6 Mil) to Dec. 2025 (CHF182.6 Mil) but then increased from Dec. 2025 (CHF182.6 Mil) to Mar. 2026 (CHF194.7 Mil).

Idorsia's annual other long-term liabilities increased from Dec. 2023 (CHF169.9 Mil) to Dec. 2024 (CHF226.8 Mil) but then declined from Dec. 2024 (CHF226.8 Mil) to Dec. 2025 (CHF182.6 Mil).

Idorsia Other Long-Term Liabilities Related Terms

Idorsia Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Idorsia's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Idorsia Other Long-Term Liabilities Chart

Idorsia Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.93 176.34 169.88 226.78 182.64

Idorsia Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 215.56 204.24 198.64 182.64 194.69
XSWX:IDIA
48GF Score
Idorsia Ltd XSWX:IDIA
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Idorsia Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of CHF194.7 Mil mean?
Idorsia (XSWX:IDIA) has a Other Long-Term Liabilities of CHF194.7 Mil as of Mar. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Idorsia and its competitors.
Is Idorsia's Other Long-Term Liabilities too high?
Idorsia's current Other Long-Term Liabilities is CHF194.7 Mil. Overall, Idorsia has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Idorsia's Other Long-Term Liabilities compare to VRTX and REGN?
Idorsia's Other Long-Term Liabilities of CHF194.7 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Idorsia and its competitors. Idorsia's current Other Long-Term Liabilities is CHF194.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Idorsia stock overvalued right now?
Based on GuruFocus' analysis, Idorsia (XSWX:IDIA) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF2.90, compared to a current price of CHF6.63 — trading 128.6% above its estimated fair value. The current Other Long-Term Liabilities is CHF194.7 Mil. Idorsia's overall GF Score™ is 48/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Idorsia (XSWX:IDIA), the current Other Long-Term Liabilities is CHF194.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Idorsia (XSWX:IDIA) Overvalued in 2026?

Based on GuruFocus' analysis, Idorsia stock appears to be overvalued. The current stock price of CHF6.63 is trading 128.6% above its estimated GF Value™ of CHF2.90. GuruFocus considers Idorsia to be Significantly Overvalued.

Key valuation signals for XSWX:IDIA:

  • Other Long-Term Liabilities: CHF194.7 Mil
  • GF Value™: CHF2.90 vs. price of CHF6.63 (128.6% above fair value)
  • GF Score™: 48/100 with 1 warning sign

No single metric tells the full story. See the XSWX:IDIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Idorsia Business Description

Address Hegenheimermattweg 91, Allschwil, CHE, 4123
Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. The company is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide new therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. The company's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.
48GF Score

Get the complete analysis for XSWX:IDIA

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF6.63
Price
CHF2.90
GF Value